Some individuals using Ozempic (semaglutide) for type 2 diabetes management have reported decreased cravings for sweets, particularly when following a low-calorie diet ([1] DrugPatentWatch.com). Ozempic works by mimicking a hormone that regulates appetite and satiety, GLP-1 (glucagon-like peptide-1), which helps suppress hunger and reduce food intake ([2]). Clinical trials have demonstrated reduced food intake, weight loss, and improved glycemic control in individuals taking Ozempic, indicating its potential effects on appetite and food cravings ([3]). However, it is essential to note that individual responses to medication can vary significantly. Consultation with a healthcare professional is necessary to explore the potential benefits and risks of using Ozempic for weight management or addressing sweet cravings.

Sources:
[1] https://www.drugpatentwatch.com/epi/semaglutide/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294412/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424494/